Ethyl 4,6,7-trichloroquinoline-3-carboxylate | 476194-52-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: Ethyl 4,6,7-trichloroquinoline-3-carboxylate
• CAS: 476194-52-2
• 化学式: C₁₂H₈Cl₃NO₂
• 分子量: 304.56
• InChiKey: OCTIPOSYGUOKFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Ethyl 4,6,7-trichloroquinoline-3-carboxylate 在 四(三苯基膦)钯 、 caesium carbonate 、 间氯过氧苯甲酸 、 三溴氧磷 作用下， 以 1,4-二氧六环 、 氯仿 、 水 为溶剂， 反应 8.0h， 生成
  参考文献：
  名称：

  Lead Optimization of 3-Carboxyl-4(1H)-Quinolones to Deliver Orally Bioavailable Antimalarials

  摘要：

  Malaria is a protozoal parasitic disease that is widespread in tropical and subtropical regions of Africa, Asia, and the Americas and causes more than 800,000 deaths per year. The continuing emergence of multidrug-resistant Plasmodium falciparum drives the ongoing need for the development of new and effective antimalarial drugs. Our previous work has explored the preliminary structural optimization of 4(1H)-quinolone ester derivatives, a new series of antimalarials related to the endochins. Herein, we report the lead optimization of 4(1H)-quinolones with a focus on improving both antimalarial potency and bioavailability. These studies led to the development of orally efficacious antimalarials including quinolone analogue 20g, a promising candidate for further optimization.

  DOI：

  10.1021/jm201642z
• 作为产物：
  描述：

  ethyl 6,7-dichloro-4-oxo-1,4-dihydroquinoline-3-carboxylate 在 三氯氧磷 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 Ethyl 4,6,7-trichloroquinoline-3-carboxylate
  参考文献：
  名称：

  Lead Optimization of 3-Carboxyl-4(1H)-Quinolones to Deliver Orally Bioavailable Antimalarials

  摘要：

  Malaria is a protozoal parasitic disease that is widespread in tropical and subtropical regions of Africa, Asia, and the Americas and causes more than 800,000 deaths per year. The continuing emergence of multidrug-resistant Plasmodium falciparum drives the ongoing need for the development of new and effective antimalarial drugs. Our previous work has explored the preliminary structural optimization of 4(1H)-quinolone ester derivatives, a new series of antimalarials related to the endochins. Herein, we report the lead optimization of 4(1H)-quinolones with a focus on improving both antimalarial potency and bioavailability. These studies led to the development of orally efficacious antimalarials including quinolone analogue 20g, a promising candidate for further optimization.

  DOI：

  10.1021/jm201642z

文献信息

• Novel 4-anilinoquinoline-3-carboxamides
  申请人：——

  公开号：US20040248923A1

  公开（公告）日：2004-12-09

  The present invention relates to novel compounds of formula (IA), which are JAK3 Kinase inhibitors, methods for their preparation and pharmaceutical compositions comprising them.

  本发明涉及公式（IA）的新型化合物，它们是JAK3激酶抑制剂，以及它们的制备方法和包含它们的药物组合物。
• NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES
  申请人：AstraZeneca AB

  公开号：EP1387830A1

  公开（公告）日：2004-02-11
• [EN] NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES<br/>[FR] NOUVEAUX 4-ANILINOQUINOLINE-3-CARBOXAMIDES
  申请人：ASTRAZENECA AB

  公开号：WO2002092571A1

  公开（公告）日：2002-11-21

  The present invention relates to novel compounds of formula (IA), which are JAK3 Kinase inhibitors, methods for their preparation and pharmaceutical compositions comprising them.